GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: GEN1184 | PRO1184 | Rina-S
Compound class:
Antibody
Comment: Rinatabart sesutecan (GEN1184; PRO1184; Rina-S) is a folate receptor alpha (FRα) antibody-drug conjugate. The payload is the topoisomerase I inhibitor exatecan (PubChem CID 151115). Designed to target ovarian and endometrial cancers that are overexpressing FRα.
|
| No information available. |
Summary of Clinical Use  |
| Rinatabart sesutecan was progressed to clinical studies to determine safety and efficacy as an anti-tumour agent. It was granted FDA fast track and breakthrough therapy designations for FRα-expressing ovarian cancer. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/Phase 2 Interventional | Genmab | The RAINFOL-01 trial | |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 Interventional | Genmab | The RAINFOL-02 trial | |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 Interventional | Genmab | ||
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy | Phase 3 Interventional | Genmab | ||
